About Dr. Wang Chaofu
Dr. Wang Chaofu is a leading pathologist and molecular diagnostics specialist in the Department of Pathology at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — one of China's most distinguished academic medical centers. With deep expertise in surgical pathology, molecular pathology, and precision oncology diagnostics, Dr. Wang is recognized as one of Shanghai's foremost authorities on the pathological diagnosis of complex tumors, the molecular profiling of cancer tissue, and the integration of next-generation sequencing (NGS) and other advanced diagnostic technologies into clinical oncology decision-making.
In the era of precision oncology, the accuracy and depth of pathological diagnosis has become the single most important determinant of treatment selection for cancer patients. The identification of actionable driver mutations, predictive biomarkers for immunotherapy response, and tumor molecular subtypes that determine eligibility for targeted therapies all depend on the quality of pathological analysis — and specifically on the expertise of the pathologist interpreting the tissue and directing the molecular testing workflow. Dr. Wang Chaofu's clinical practice sits at the intersection of traditional surgical pathology and cutting-edge molecular diagnostics, enabling him to provide international patients and their oncologists with the comprehensive, molecularly-informed pathological assessments that are essential for optimal treatment planning in 2025 and beyond.
For international patients who arrive at Ruijin Hospital with prior pathology reports from their home countries — or who require fresh biopsy or surgical specimen analysis as part of their diagnostic workup in Shanghai — Dr. Wang's team provides pathological review and molecular profiling services that frequently yield clinically actionable information not captured by standard pathology workflows: identification of rare driver mutations, assessment of tumor mutational burden (TMB) and microsatellite instability (MSI) status for immunotherapy eligibility, detection of fusion genes amenable to targeted therapy, and comprehensive molecular subtyping that refines prognosis and guides treatment sequencing.
Hospital Affiliation: Department of Pathology, Ruijin Hospital
Ruijin Hospital (瑞金医院), affiliated with Shanghai Jiao Tong University School of Medicine, is one of Shanghai's oldest and most respected academic medical institutions, founded in 1907 and consistently ranked among China's top hospitals. Its Department of Pathology is a high-volume, technologically advanced diagnostic laboratory serving one of Shanghai's busiest tertiary referral hospitals, processing thousands of surgical specimens, biopsies, and cytology samples annually across all major organ systems and tumor types.
The department's molecular pathology laboratory is equipped with the full range of contemporary diagnostic platforms: next-generation sequencing (NGS) for comprehensive tumor genomic profiling, fluorescence in situ hybridization (FISH) for gene amplification and fusion detection, immunohistochemistry (IHC) for protein expression and predictive biomarker assessment (PD-L1, HER2, MMR proteins, ALK, ROS1, and others), polymerase chain reaction (PCR) for mutation detection and microsatellite instability analysis, and RNA sequencing for fusion gene identification and gene expression profiling. The department maintains active research collaborations with oncology teams across Ruijin Hospital's clinical departments and with international pathology and oncology centers, and participates in national and international quality assurance programs for molecular diagnostics.
For international patients, Ruijin Hospital's pathology department offers access to comprehensive molecular profiling capabilities — including large-panel NGS tumor profiling that may not be routinely available or affordable in their home healthcare systems — at costs substantially below those of equivalent testing in Western countries, with turnaround times that support timely clinical decision-making.
Clinical Specialties: What Dr. Wang Chaofu Provides
- Surgical pathology and expert second opinion — comprehensive histopathological review of tumor specimens including resection specimens, core needle biopsies, and fine needle aspirates; expert second opinion on difficult or diagnostically challenging cases including rare tumors, tumors of uncertain histogenesis, and cases where the primary diagnosis is in question; re-review of outside pathology slides and blocks with updated immunohistochemical and molecular analysis
- Comprehensive tumor molecular profiling (NGS) — large-panel next-generation sequencing of tumor tissue for identification of actionable driver mutations (EGFR, KRAS, BRAF, PIK3CA, ERBB2, MET, RET, NTRK, and others), assessment of tumor mutational burden (TMB), microsatellite instability (MSI) status, copy number alterations, and structural variants including fusion genes; comprehensive genomic profiling reports with clinical annotation and treatment implications
- Predictive biomarker assessment for targeted therapy and immunotherapy — PD-L1 expression by immunohistochemistry (multiple validated antibody clones); HER2 status by IHC and FISH for breast, gastric, and other HER2-driven tumors; ALK, ROS1, RET, MET, and NTRK status by IHC and/or FISH; MMR protein expression and MSI status for immunotherapy eligibility; EGFR mutation analysis for lung adenocarcinoma; BRCA1/2 status for ovarian and breast cancer
- Hematopathology and lymphoma diagnosis — comprehensive immunophenotyping and molecular characterization of lymphomas, leukemias, and other hematological malignancies; flow cytometry, IHC panel analysis, cytogenetics, and molecular studies for accurate WHO classification; assessment of minimal residual disease (MRD) markers
- Neuropathology and brain tumor diagnosis — integrated histological and molecular diagnosis of gliomas and other brain tumors according to the 2021 WHO Classification of Tumors of the Central Nervous System, including IDH mutation status, 1p/19q codeletion, MGMT promoter methylation, TERT promoter mutation, EGFR amplification, and other diagnostically and prognostically relevant molecular markers
- Gastrointestinal and hepatobiliary pathology — expert diagnosis of colorectal, gastric, esophageal, hepatocellular, cholangiocarcinoma, and pancreatic tumors; molecular profiling for treatment selection including MSI/MMR status, HER2 amplification, KRAS/NRAS/BRAF mutation analysis, and FGFR2 fusion detection in cholangiocarcinoma
- Liquid biopsy and circulating tumor DNA (ctDNA) analysis — plasma-based ctDNA profiling for patients where tissue biopsy is not feasible or where serial monitoring of treatment response and resistance mechanisms is required; integration of liquid biopsy results with tissue-based molecular profiling for comprehensive genomic assessment
The Role of Molecular Pathology in Precision Oncology
The transformation of cancer treatment over the past two decades — from cytotoxic chemotherapy applied uniformly across tumor types to molecularly targeted therapies and immunotherapies selected on the basis of specific tumor biomarkers — has made the quality of pathological and molecular diagnosis the central determinant of treatment outcome for many cancer patients. A patient with lung adenocarcinoma harboring an EGFR exon 19 deletion who receives an EGFR tyrosine kinase inhibitor has a median progression-free survival of 18–19 months; the same patient treated with chemotherapy because the EGFR mutation was not detected has a median progression-free survival of 5–6 months. A patient with MSI-high colorectal cancer who receives pembrolizumab has a response rate exceeding 40% and durable long-term remissions; the same patient treated with standard chemotherapy has a response rate of 5–10% and no durable benefit from immunotherapy.
These examples illustrate a principle that applies across virtually every major tumor type: the accuracy and completeness of molecular profiling directly determines whether patients receive the treatments most likely to benefit them. Dr. Wang Chaofu's expertise lies in ensuring that the pathological and molecular assessment of each patient's tumor is as accurate, complete, and clinically actionable as possible — and in communicating the results and their treatment implications in a way that enables oncologists and patients to make well-informed decisions.
For international patients who have received pathological diagnoses in their home countries, a second opinion review by Dr. Wang's team at Ruijin Hospital frequently adds clinically significant information: identification of molecular alterations not tested for in the original workup, reclassification of tumor histology or subtype with treatment implications, detection of discordant IHC results that affect biomarker-driven treatment eligibility, and comprehensive genomic profiling that opens access to targeted therapies or clinical trials not previously considered.
Why International Patients Choose Dr. Wang Chaofu and Ruijin Hospital
International patients seek pathological consultation and molecular profiling services from Dr. Wang Chaofu and Ruijin Hospital's Department of Pathology for several overlapping reasons.
First, the comprehensiveness and technical depth of the molecular profiling available at Ruijin Hospital — including large-panel NGS tumor profiling, comprehensive fusion gene detection, and the full range of predictive biomarker assessments — frequently exceeds what is routinely available in community oncology settings in their home countries, where molecular testing may be limited to a small number of single-gene assays or narrow panels. For patients with rare tumors, tumors of uncertain histogenesis, or tumors that have not responded to standard treatment, comprehensive molecular profiling at Ruijin Hospital may identify actionable alterations that open access to targeted therapies or clinical trials not previously available to them.
Second, the cost of comprehensive molecular profiling at Ruijin Hospital is substantially lower than equivalent testing in Western healthcare systems, where large-panel NGS tumor profiling may cost several thousand dollars and may not be covered by insurance for all tumor types and clinical indications. The combination of high technical quality and cost-effectiveness makes Ruijin Hospital an attractive destination for patients seeking comprehensive molecular profiling as part of their oncological workup.
Third, for patients who are already traveling to Shanghai for oncological consultation or treatment at Ruijin Hospital or another Shanghai institution, integrating pathological review and molecular profiling into the same visit — coordinated through CMCS — provides a seamless, efficient diagnostic experience that minimizes the time and logistical complexity of the workup.
Finally, for patients with diagnostically challenging cases — rare tumors, tumors with unusual morphology or immunophenotype, or cases where the primary diagnosis is uncertain — Dr. Wang's expertise in difficult surgical pathology and his access to the full range of ancillary diagnostic techniques available at Ruijin Hospital make him a valuable resource for expert second opinion that may resolve diagnostic uncertainty and enable appropriate treatment planning.
What to Expect at Your Consultation
Pathological consultations and molecular profiling services arranged through CMCS at Ruijin Hospital's Department of Pathology begin with a review of all prior pathology reports, immunohistochemistry results, and molecular testing results, as well as the patient's oncological history, treatment records, and current clinical status. For patients seeking expert second opinion on prior pathology, CMCS will coordinate the transfer of pathology slides, tissue blocks, or digitized whole-slide images to Ruijin Hospital for review. For patients requiring fresh biopsy or surgical specimen analysis, CMCS will coordinate the biopsy or surgical procedure and ensure that specimen handling and processing are optimized for the planned molecular testing workflow.
Dr. Wang's team will provide a comprehensive pathological assessment including histological diagnosis, immunohistochemical panel results, and the results of all molecular testing performed, with detailed clinical annotation of the treatment implications of each finding. A written English-language pathology report and molecular profiling summary is provided after every consultation, and CMCS will facilitate direct communication between Dr. Wang's team and the patient's home oncologist for integration of the pathological findings into the overall treatment plan.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides comprehensive end-to-end support for international patients seeking pathological consultation and molecular profiling services with Dr. Wang Chaofu at Ruijin Hospital. Our services include priority scheduling with Dr. Wang's team, coordination of pathology slide and tissue block transfer for second opinion review, certified translation of prior pathology reports and molecular testing results, coordination of fresh biopsy procedures where required, on-site interpretation throughout the consultation process, and written English-language reporting of all pathological and molecular findings. CMCS will also facilitate direct communication between Dr. Wang's team and the patient's home oncologist to ensure seamless integration of the Ruijin Hospital pathological assessment into the patient's overall oncological care plan.
📧 contract@medicalsh.com | 💬 WeChat: gezhanglao | 🌐 medicalsh.com
0 comentarios